Status:
UNKNOWN
Beta-glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT)
Lead Sponsor:
University of Bologna
Conditions:
Atherosclerosis
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
This will be a randomized, placebo-controlled, clinical trial carried out on moderately hypercholesterolemic subjects who will consume 3 g per day of beta-glucans, in order to evaluate the effects on ...
Detailed Description
In order to assess the mid term effects of beta-glucans on lipid profile, glycemia and intestinal function, moderately hypercholesterolemic subjects will be involved in a cross-over study and suppleme...
Eligibility Criteria
Inclusion
- Total cholesterol between 200 and 240 mg/dL and/or LDL cholesterol between 130 and 190 mg/dL
- Triglycerides lower than 200 mg/dL
- Cardiovascular risk at 10 years lower than 10%
- Informed consent
Exclusion
- Secondary prevention for cardiovascular diseases
- TG \> 400 mg/dL, HDL-C \< 35 mg/dL
- BMI higher than 30
- Assumption of lipid lowering drug or supplement with fibre or probiotics during the last 2 months
- Alcohol abuse
- Food allergy
- Alterations in thyroid, liver, or kidney functions, muscle diseases
- Diabetes, irritable bowel syndrome or chronic disturbed gut function
Key Trial Info
Start Date :
April 26 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT03313713
Start Date
April 26 2017
End Date
March 1 2018
Last Update
October 19 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
S. Orsola-Malpighi University Hospital
Bologna, BO, Italy, 40138